Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Terrie J. Curran | President, CEO & Director | 1.22M | -- | 1969 |
| Mr. David A. Socks | Co-Founder & Director | 54.17k | -- | 1975 |
| Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder & COO | 888.9k | -- | 1959 |
| Ms. Molly Henderson CPA, MBA | Chief Financial & Business Officer | 777.76k | -- | 1971 |
| Dr. Aditya Kohli Ph.D. | Co-Founder | 319.65k | -- | 1988 |
| Mr. Paul Cocja | Chief People Officer | -- | -- | -- |
| Mr. Tom Harris | Chief Development Sciences Officer | -- | -- | -- |
| Dr. Eckhard Leifke M.D., Ph.D. | Chief Medical Officer | -- | -- | -- |
| Mr. Martin J. Gilligan | Chief Commercial Officer | -- | -- | -- |
Phathom Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 452
Description
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Corporate Governance
Upcoming Events
March 5, 2025 at 1:30 PM UTC - March 10, 2025 at 1:30 PM UTC
Phathom Pharmaceuticals, Inc. Earnings Date
Recent Events
June 14, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission